Twice-Daily Lotilaner Ophthalmic Solution Effective Treatment of Patients with Demodex Blepharitis

ReachMD Healthcare Image


Twice-daily treatment with lotilaner ophthalmic solution,holds promise for the effective treatment of patients with Demodex blepharitis suggests a new study published in the Opthalmology.

A study was done to evaluate the safety and efficacy of lotilaner ophthalmic solution, 0.25% compared to the vehicle for the treatment of Demodex blepharitis.

Four hundred and twelve (412) Demodex blepharitis patients were randomly assigned in a 1:1 ratio to receive either lotilaner ophthalmic solution, 0.25% (study group) or vehicle without lotilaner (control group).

In this study, conducted at 21 U.S. clinical sites, Demodex blepharitis patients assigned to the study group (N=203) received lotilaner ophthalmic solution, 0.25% and those in the control group (N=209) received vehicle without lotilaner bilaterally, twice daily for six weeks. Patients were evaluated on Days 8, 15, 22, and 43. Collarettes and erythema were graded for each eyelid at screening and at all post-baseline visits. At screening, and on Days 15, 22, and 43, 4 or more eyelashes were epilated from each eye, and the number of Demodex mites present on the lashes was counted with a microscope. Mite density was calculated as the number of mites per lash.

Outcome measures included collarette cure (collarette grade 0), clinically meaningful collarette reduction to ≤10 collarettes (grade 0 or 1), mite eradication (0 mites/lash), erythema cure (grade 0), composite cure (grade 0 for collarettes as well as erythema), compliance with the drop regimen, drop comfort, and adverse events.


At Day 43, the study group achieved a statistically significant (p<0.0001) higher proportion of patients with collarette cure (56.0% vs 12.5%), clinically meaningful collarette reduction to ≤10 collarettes (89.1% vs 33.0%), mite eradication (51.8% vs 14.6%), erythema cure (31.1% vs 9.0%), and composite cure (19.2% vs 4.0%) than the control group. High compliance with the drop regimen (mean ± standard deviation: 98.7 ± 5.3%) in the study group was observed, and 90.7% of patients found the drops to be neutral to very comfortable.

Twice-daily treatment with lotilaner ophthalmic solution, 0.25% for 6 weeks was generally safe and well tolerated and met the primary endpoint and all secondary endpoints for the treatment of Demodex blepharitis compared to the vehicle control.


Ian Benjamin Gaddie, Eric D. Donnenfeld, Paul Karpecki, John Meyer, Elizabeth Yeu, Saturn II Study Group. Lotilaner Ophthalmic Solution, 0.25% for Demodex Blepharitis: Randomized, Vehicle-Controlled, Multicenter, Phase 3 Trial (Saturn-2). Published:June 05, 2023DOI:

Facebook Comments


We’re glad to see you’re enjoying Prova Education…
but how about a more personalized experience?

Register for free